MD1003 (High-Dose Biotin) for the treatment of progressive multiple sclerosis: baseline data and results from a cohort of patients included in a early access program

被引：0
|
作者：
Brassat, D. [1 ]
Hautecoeur, P. [2 ]
Durand-Dubief, F. [3 ]
Castelnovo, G. [4 ]
Derache, N. [5 ]
Bourre, B. [6 ]
Le Page, E. [7 ]
Donze, C. [8 ]
Audoin, B. [9 ]
Ouallet, J-C. [10 ]
Collongues, N. [11 ]
Simon, O. [12 ]
Brion, G. [12 ]
Vermersch, P. [13 ]
机构：
[1] Hop Pierre Paul Riquet, Dept Neurol, Toulouse, France
[2] Catholic Inst Lille, Grp Hop, Lomme Les Lille, France
[3] Pierre Wertheimer Hosp, Dept Neurol, Rhone, France
[4] Caremeau Hosp, Dept Neurol, Nimes, France
[5] CHU Caen, Caen, France
[6] Rouen Normandy Univ, Rouen, France
[7] Univ Hosp Pontchaillou, Rennes, France
[8] Catholic Inst Lille, Grp Hop, Lille, France
[9] Hop la Timone, APHM, Serv Neurol, Marseille, France
[10] CHU Pellegrin, Bordeaux, France
[11] Univ Hosp Strasbourg, Dept Neurol, Strasbourg, France
[12] Medday Pharmaceut, Paris, France
[13] Univ Lille, Lille, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1776
引用
收藏
页码：936 / 937
页数：2
相关论文
共 50 条
  • [1] MD1003 (High-Dose Pharmaceutical Biotin) for the Treatment of Progressive Multiple Sclerosis: Baseline Data and Results from an Early Access Program
    Brassat, David
    Hautecoeur, Patrick
    Durand-Dubief, Francoise
    Castelnovo, Giovanni
    Derache, Nathalie
    Bourre, Bertrand
    Donze, Cecile
    Ouallet, Jean-Christophe
    Collongues, Nicolas
    Simon, Olivier
    Brion, Guillaume
    Sedel, Frederic
    Vermersch, Patrick
    Lasser, Robert
    Morteau, Olivier
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 31 - 32
  • [2] Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis
    Saint Paul, Laure Peyro
    Debruyne, Daniele
    Bernard, Delphine
    Mock, Donald M.
    Defer, Gilles L.
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (03) : 327 - 344
  • [3] Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high-dose pharmaceutical-grade biotin (MD1003)
    Collongues, Nicolas
    Kuhle, Jens
    Tsagkas, Charidimos
    Lamy, Julien
    Meyer, Nicolas
    Barro, Christian
    Parmar, Katrin
    Amann, Michael
    Wuerfel, Jens
    Kappos, Ludwig
    Moreau, Thibault
    Seze, Jerome
    [J]. BRAIN AND BEHAVIOR, 2021, 11 (02):
  • [4] Annual Relapse Rates (ARR) in Patients with Spinal Progressive Multiple Sclerosis Treated with MD1003 (High-Dose Pharmaceutical Biotin)
    Morteau, Olivier
    Lasser, Robert
    Sedel, Frederic
    Brion, Guillaume
    Tourbah, Ayman
    Simon, Olivier
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 31 - 31
  • [5] Effect of MD1003 (High-Dose Biotin) in spinal progressive multiple sclerosis (MS-SPI): subgroup analyses
    Laplaud, D. -A.
    Gout, O.
    Clavelou, P.
    Pelletier, J.
    Sedel, F.
    Tourbah, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 402 - 403
  • [6] MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
    Tourbah, Ayman
    Lebrun-Frenay, Christine
    Edan, Gilles
    Clanet, Michel
    Papeix, Caroline
    Vukusic, Sandra
    De Seze, Jerome
    Debouverie, Marc
    Gout, Olivier
    Clavelou, Pierre
    Defer, Gilles
    Lapland, David-Axel
    Moreau, Thibault
    Labauge, Pierre
    Brochet, Bruno
    Sedel, Frederic
    Pelletier, Jean
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (13) : 1719 - 1731
  • [7] Effect of MD1003 (High-Dose Pharmaceutical Biotin) in Spinal Progressive Multiple Sclerosis (MS-SPI): Subgroup Analyses
    Laplaud, David-Axel
    Gout, Olivier
    Clavelou, Pierre
    Pelletier, Jean
    Simon, Olivier
    Sedel, Frederic
    Tourbah, Ayman
    Lasser, Robert
    Morteau, Olivier
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 33 - 33
  • [8] Long term effect of MD1003 (high dose pharmaceutical grade biotin) in a cohort of patients with progressive non-active multiple sclerosis
    Donze, C.
    Guyot, M. A.
    Kwiatkowski, A.
    Hautecoeur, P.
    Massot, C.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 385 - 385
  • [9] NFL pattern in progressive Multiple Sclerosis cohort under MD1003 treatment
    Pignolet, Beatrice
    Ammoscato, Francesca
    Ciron, Jonathan
    Bucciarelli, Florence
    Scandella, Lise
    Biotti, Damien
    Lerebours, Fleur
    Dorcet, Guillaume
    Rabadeux, Celine
    Freitas, Noellie
    Bonneville, Fabrice
    Gnanapavan, Sharmilee
    Brassat, David
    [J]. NEUROLOGY, 2019, 92 (15)
  • [10] Comorbidities and safety of use of MD1003 in a cohort of patients with progressive multiple sclerosis
    Donze, C.
    Cattoir, H.
    Hautecoeur, P.
    Kwiatkowski, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 817 - 818
12345